Skip to content

Pragmatic Randomized Clinical Trial to Limit Weight Gain in Pregnancy and Prevent Obesity

Healthy for 2/Healthy for U: A Pragmatic Randomized Clinical Trial to Limit Gestational Weight Gain and Prevent Obesity in Johns Hopkins Prenatal Care Practices

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04724330
Acronym
H42/H4U
Enrollment
534
Registered
2021-01-26
Start date
2021-03-15
Completion date
2025-06-25
Last updated
2026-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood Obesity, Gestational Diabetes, Overweight and Obesity, Postpartum Weight Retention, Pregnancy Weight Gain

Brief summary

Healthy for Two, Healthy for You (H42/H4U) is an innovative evidence-based pregnancy/postpartum health coach intervention that is remotely-delivered (phone coaching using motivational interviewing, web-based platform, mobile phone behavioral tracking). The aim of this randomized controlled trial (RCT) is to embed H42/H4U into Johns Hopkins prenatal care clinics that serve a racially and economically diverse population, leveraging existing staff as trained health coaches to test its effectiveness and implementation. The investigators hypothesize that women in the H42/H4U arm will have lower gestational weight gain and lower rates of gestational diabetes, without an increase in low birth weight infants, and that implementation into the investigators' prenatal care clinics will be feasible and scalable.

Detailed description

Despite two decades of public health efforts to combat obesity, rates continue to rise and racial disparities persist. There is an urgent need to re-focus obesity prevention efforts onto young adults, particularly reproductive age women. 23% of women (vs. 13% of men) gain ≥20 kg from age 18 to 55 years, with the highest weight gain in African American women who gain \> 1kg/year. Importantly, weight gain of ≥20 kg is associated with development of type 2 diabetes (DM), other obesity-related comorbidities and greater mortality. For women who become pregnant, pregnancy provides an important opportunity for obesity and DM prevention, as excessive gestational weight gain (GWG) and pregnancy complications \[e.g. gestational diabetes (GDM)\], increase future DM risk. Promoting healthy GWG through behavioral interventions may prevent these pregnancy complications, but importantly has great potential for long-term, sustainable benefits to prevent postpartum weight retention (PPWR) and future obesity and DM, in women and the women's children. With the publication of the LIFE-Moms consortium's results, there is now strong evidence from efficacy trials showing that limiting GWG is achievable and associated with improved exercise and dietary behaviors. Several notable research gaps and next steps have emerged from the LIFE-Moms' studies, which the investigators address in this pragmatic trial. Because these studies were designed to test the efficacy of behavioral weight management on GWG, interventions were resource intensive (i.e. in-person counseling and with limited online and mobile technologies), without a focus on program implementation and sustainability in routine prenatal care settings and lacking intervention in the vulnerable postpartum period. To address these critical evidence gaps and reduce obesity associated with the pregnancy/postpartum periods, the next step is to integrate and test an evidence-based lifestyle intervention in pregnancy and postpartum that utilizes remote delivery of counseling, enables self-monitoring by patients using mobile and online technologies and supports obstetric providers and clinics to optimize care for women at high risk for obesity and future DM. The investigators' experienced team created and tested Healthy for Two / Healthy for You (H42/H4U). H42/H4U is an innovative evidence-based pregnancy/postpartum health coaching intervention that is remotely-delivered (phone coaching using motivational interviewing + web-based platform + mobile phone behavioral tracking). The aim of this R18 pragmatic randomized controlled trial (RCT) is to embed H42/H4U into prenatal care clinics that serve a racially and economically diverse population, leveraging existing staff as trained health coaches and community health workers (CHWs), to test its effectiveness and implementation. The investigators hypothesize that women in the H42/H4U arm will have lower GWG and lower rates of GDM, without an increase in low birth weight infants, and that implementation into the investigators' prenatal care clinics will be feasible and scalable. The investigators will rigorously test this hypothesis through the following Specific Aims: Aim 1. Test the effectiveness of H42/H4U integrated into prenatal care compared with Usual Care among 380 pregnant and postpartum women enrolled from 6 prenatal clinics on: A. Primary outcome: GWG (37 week minus baseline pregnancy \[≤15 week gestation\] weight) B. Maternal secondary outcomes: Proportion with excessive GWG; GDM incidence; PPWR at 6 months after delivery C. Infant secondary outcomes: Weight at birth, 4 and 6 months. D. Other outcomes: Maternal health behaviors (diet, physical activity, breastfeeding); Maternal wellness (depression, sleep and stress) Aim 2. Assess organizational factors that impact the implementation of the intervention into prenatal care clinics, including costs of intervention delivery and provider and staff satisfaction to inform future dissemination. A. Provider and staff perspectives, including satisfaction, workflow barriers and potential for sustainability, using qualitative semi-structured interviews (n=15 at baseline and end of study). B. Cost analysis to assess intervention delivery costs and the return on investment (ROI) of H42/H4U. This study will advance a potentially powerful, prenatal care-based strategy to reduce obesity in young adult childbearing women and thereby the intergenerational effects on the women's children. The investigators' interdisciplinary team brings together engaged academic and community-based obstetricians, the investigators' health system's population health program and researchers with experience in developing, testing and implementing behavioral interventions in both pregnant and non-pregnant adults in real world settings to enable wide dissemination. Ultimately, the investigators' goal is to design and produce an effective and scalable behavioral strategy, integrated into clinical practice that will: 1) reduce excessive GWG and its associated pregnancy complications, 2) reduce future obesity, DM and other obesity-related complications in mothers and the mothers' children, and 3) ensure high quality care delivery that prevents obesity and DM through a population health approach to prenatal care.

Interventions

BEHAVIORALHealthy for Two/Healthy for You

\~10 month (early pregnancy to 12 weeks postpartum), remotely-delivered, behavioral lifestyle intervention including health coach contacts (via phone, videoconference, and email/MyChart) and an interactive web-based platform.

Sponsors

Johns Hopkins University
Lead SponsorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age≥18 * Singleton pregnancy * ≤15 weeks gestation with documented prenatal weight and height in electronic health record * Body mass index ≥ 25.0 kg/m2 * English-speaking * Has smartphone, laptop or tablet and willing to use it for this study * Has email address and willing to use for this study

Exclusion criteria

* BMI \<25 kg/m2 * Multiple fetuses * History of pre-gestational Type 1 or Type 2 diabetes or taking diabetes medication for treatment of diabetes prior to first prenatal visit * Prior history of severe preeclampsia, pre-term birth (\< 32 weeks gestation) * Poorly controlled blood pressure (\> 160/100 mmHg) * Substance use disorder or positive urine toxicology (except for THC) for illicit substances (screening done as part of routine care) * Psychiatric hospitalization in last 12 months or diagnosis of severe mental illness that is not well controlled * Active diagnosis of an eating disorder * Unable to walk 1 block without pain or shortness of breath * No email address * Unable to speak or read in English * Planning to move in next 12 months

Design outcomes

Primary

MeasureTime frameDescription
Observed Total Gestational Weight GainAt 37 weeks in pregnancyObserved difference between weight (lbs) at 37 weeks and baseline first trimester weight, measured prior to 15 weeks gestation.

Secondary

MeasureTime frameDescription
Observed Incidence of Gestational Diabetes MellitusAt 37 weeks in pregnancyDefined and validated by electronic health record diagnosis.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORWendy L Bennett, MD, MPH

Johns Hopkins University

Participant flow

Recruitment details

Participants were recruited based on clinical referral at 9 academic and community-based obstetrics practices.

Pre-assignment details

Of 534 pregnant women consented, 384 met the inclusion criteria and were randomized.

Baseline characteristics

Characteristic
Age, Continuous32.8 years
STANDARD_DEVIATION 5
Body Mass Index (BMI)
25-29.9
67 Participants
Body Mass Index (BMI)
30-39.9
95 Participants
Body Mass Index (BMI)
>= 40
34 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
34 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
176 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
3 Participants
Participant Prenatal recruitment practices
Community-based practice
90 Participants
Participant Prenatal recruitment practices
Federal qualified health center practice
11 Participants
Participant Prenatal recruitment practices
Hospital-affiliated faculty practice
90 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
11 Participants
Race (NIH/OMB)
Black or African American
114 Participants
Race (NIH/OMB)
More than one race
22 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
3 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
105 Participants
Sex: Female, Male
Female
187 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 3741 / 380
other
Total, other adverse events
24 / 37424 / 380
serious
Total, serious adverse events
3 / 3741 / 380

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 3, 2026